[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555785":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":24,"responsibleParty":64,"collaborators":7,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":7,"enrollmentInfo":77,"targetDuration":7,"studyType":80,"phases":7,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"University of Trieste","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"no intervention","observational study, the patients received corticosteroids according to the physician on duty",[13],{"name":14,"affiliation":5,"role":15},"MARCO CONFALONIERI, MD","PRINCIPAL_INVESTIGATOR",[17,21],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","+390403994667","mconfalonieri@units.it",{"name":22,"role":18,"phone":19,"phoneExt":7,"email":23},"Francesco Salton, MD","francesco.salton@gmail.com",[25,54],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Marco Confalonieri","RECRUITING","Trieste","TS","34149","Italy","IT",{"type":34,"coordinates":35},"Point",[36,37],13.77678,45.64953,{"lat":37,"lon":36},[40,44,46,48,50,52],{"name":41,"role":18,"phone":42,"phoneExt":43,"email":20},"marco confalonieri, MD","+39040399","4667",{"name":22,"role":18,"phone":45,"phoneExt":7,"email":23},"+393486986287",{"name":47,"role":15,"phone":7,"phoneExt":7,"email":7},"Sergio Harari, Prof",{"name":49,"role":15,"phone":7,"phoneExt":7,"email":7},"Michele Mondoni, Prof.",{"name":51,"role":15,"phone":7,"phoneExt":7,"email":7},"Umberto Zuccon, Dr.",{"name":53,"role":15,"phone":7,"phoneExt":7,"email":7},"Jesus Vilar, Dr",{"facility":55,"status":27,"city":28,"state":7,"zip":56,"country":31,"countryCode":32,"cosmosGeoPoint":57,"geoPoint":59,"contacts":60},"SC Pneumologia, Azienda Sanitaria Universitaria Giuliano-Isontina","34126",{"type":34,"coordinates":58},[36,37],{"lat":37,"lon":36},[61],{"name":22,"role":18,"phone":62,"phoneExt":7,"email":63},"00390403994667","francesco.salton@asugi.sanita.fvg.it",{"type":15,"investigatorFullName":65,"investigatorTitle":66,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Confalonieri Marco, MD","Prof.","100555785","fulminant-severe-cap---an-observational-study-100555785",false,"NCT06516601","Fulminant Severe CAP - an Observational Study","Fulminant Cases Among Severe Community-acquired Pneumonia - an Observational Retrospective Study","FULMISCAP","Inclusion Criteria: severe community acquired pneumonia according to ATS\u002FIDSA -\n\nExclusion Criteria: incomplete outcome data\n\n\\-","ALL","18 Years",{"count":78,"type":79},1460,"ESTIMATED","OBSERVATIONAL","Severe community-acquired pneumonia (CAP) represents a major cause of hospital mortality. Among severe CAP cases, some exhibit a rapidly progressive evolution, leading to severe ARDS\u002Facute respiratory failure and septic shock within hours to a few days. This type of pneumonia, known as \"fulminant pneumonia,\" is characterized by its rapid onset and deterioration, often necessitating immediate medical intervention. Despite its severity, the true incidence and optimal treatment for fulminant pneumonia are not well understood. This knowledge gap is due to the lack of attention towards pneumonia as a potential time-dependent illness and the separation of overlapping clinical topics: severe pneumonia, ARDS, and sepsis.\n\nIn clinical practice, pneumonia is the most frequent cause of both ARDS and sepsis. However, these conditions are often considered separately, combining ARDS and sepsis from various extra-pulmonary causes with those originating from pneumonia. The COVID-19 pandemic, with its vast number of severe CAP cases in a short period, has highlighted the existence of fulminant pneumonias, underscoring the need for further investigation. Recent randomized clinical trials (RCTs) and experiences from COVID-19 have suggested that early and prolonged corticosteroid administration can reduce mortality in patients with severe SARS-CoV-2 infection and severe CAP\u002FARDS of bacterial origin.\n\nThe aim of this observational study is to analyze the rate of fulminant pneumonia and assess the impact of early corticosteroid treatment in a multicentric population of hospitalized patients with severe pneumonia.",[83,84,85,86],"Community-acquired Pneumonia","Severe Pneumonia","ARDS, Human","Sepsis",[88,89,90,91,92],"fulminant pneumonia","community acquired pneumonia","ARDS","sepsis","corticosteroids","2024-07-17",{"date":95,"type":96},"2024-07-24","ACTUAL",{"date":98,"type":96},"2018-01-02",{"date":100,"type":79},"2024-10-01",{"name":5,"class":6},2]